Scott Sellinger, MD, FACS, explains the biologic significance of PTEN loss in metastatic prostate cancer, why it is associated with aggressive disease and poor outcomes, and how the approval of capivasertib has transformed PTEN from a prognostic biomarker into a predictive biomarker with a targeted treatment option.
In this video, Scott Sellinger, MD, FACS, discusses how PTEN testing may become increasingly integrated into the routine evaluation of patients with newly diagnosed metastatic prostate cancer following the FDA approval of capivasertib (Truqap) for patients with PTEN-deficient disease identified by an FDA-authorized test.
The phase 3 CAPItello-281 trial (NCT04493853) met its primary end point by showing that the addition of capivasertib (Truqap) to abiraterone (Zytiga) and prednisone significantly improved radiographic progression-free survival (rPFS) vs abiraterone and prednisone alone in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
